RBC Capital lowered the firm’s price target on Moderna (MRNA) to $62 from $75 and keeps a Sector Perform rating on the shares following a COVID vaccine sale beat that was primarily driven by an ...

Nov 7 (Reuters) - 3M spin-off Solventum (SOLV.N), opens new tab raised its annual profit forecast on Thursday, betting on strong sales of its wound care and surgical sterilization products. The ...

Moderna posted a surprising third-quarter profit, driven by cost-cutting and higher-than-expected Covid vaccine sales.

Health officials say it's important to get flu and COVID-19 vaccines ahead of the holidays when respiratory bugs tend to ...

Moderna reported earnings that exceeded expectations due to effective cost management but still has challenges related to its ...

Moderna Inc.'s stock was higher but off its early highs Thursday, after the company's third-quarter earnings showed an unexpected profit as well as revenue that beat estimates by a wide margin. The ...

Moderna reported better third-quarter results than expected Thursday morning, as the vaccine maker reported a surprise profit for the period amid its efforts to cut costs and $1.8 billion in sales of ...

Sales of Moderna’s COVID-19 shot exceeded expectations, but the company’s launch of its new RSV vaccine has started slowly.

Attend Pittcon 2025 in Boston to connect with global leaders in laboratory science and explore cutting-edge advancements in ...

While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday ...